8-K
INTEGRATED BIOPHARMA INC (INBP)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
May 14, 2025
________________
INTEGRATED BIOPHARMA, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
Delaware
(STATE OR OTHER JURISDICTION OF INCORPORATION)
| 001-31668 | 22-2407475 |
|---|---|
| (COMMISSION FILE NUMBER) | (I.R.S. EMPLOYER IDENTIFICATION NO.) |
225 Long Avenue
Hillside, New Jersey 07205
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
(973) 926-0816
(REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Exchange Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| None | None | None |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On May 14, 2025, Integrated Biopharma, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 hereto and is hereby incorporated by reference into this Item 2.02.
The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
| 99.1 | Press Release dated May 14, 2025 |
|---|---|
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
-1-
EXHIBIT INDEX
| Exhibit | Description |
|---|---|
| 99.1 | Press Release dated May 14, 2025 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
-2-
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INTEGRATED BIOPHARMA, INC. | |
|---|---|
| Date: May 14, 2025 | By: /s/ Dina L Masi |
| Dina L Masi | |
| Chief Financial Officer |
-3-
ex_145031.htm
Exhibit 99.1
NEWS RELEASE for May 14, 2025
Contact: Dina Masi, CFO
Integrated BioPharma, Inc.
investors@ibiopharma.com
888.319.6962
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2025
HILLSIDE, NEW JERSEY (May 14, 2025) - Integrated BioPharma, Inc. ((OTCQX: INBP)) (the “Company” or “INBP”) reports its financial results for the quarter ended March 31, 2025.
Revenue for the quarter ended March 31, 2025 was $13.9 million compared to $13.1 million for the quarter ended March 31, 2024, an increase of $0.8 million or 6.1%. The Company had operating income in the quarter ended March 31, 2025 of approximately $0.7 million compared to $0.4 million in the quarter ended March 31, 2024.
Revenue for the nine-month period ended March 31, 2025 was $40.2 million compared to $37.6 million for the nine-month period ended March 31, 2024, an increase of $2.6 million or 6.9%. The Company had operating income for the nine-month period ended March 31, 2025 of approximately $1.4 million and an operating loss of approximately $0.2 million for the nine-month period ended March 31, 2024.
For the quarters ended March 31, 2025 and 2024, the Company had net income of approximately $0.6 million and $0.3 million, respectively. The Company’s net income per share of common stock and diluted net income per share of common stock for the quarters ended March 31, 2025 and 2024 were $0.02 and $0.01 per share of common stock, respectively.
For the nine-month periods ended March 31, 2025 and 2024, the Company had net income of approximately $1.0 million and a net loss of approximately $0.2 million, respectively. The Company’s net income (loss) per share of common stock and diluted net income (loss) per share of common stock for the nine months ended March 31, 2025 and 2024 were $0.03 and $(0.01), respectively.
“Our revenues increased by 6.9% in the nine months ended March 31, 2025 compared to the comparable period a year ago. Our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 83% and 90% of total revenue in the nine-month period ended March 31, 2025 and 2024, respectively,” stated the Co-Chief Executive Officers of the Company, Riva Sheppard and Christina Kay. “We are happy to report that while focusing on our core business we were able to expand our customer base over the past year and increase our revenue,” the Co-CEOs further stated.
A summary of our financial results for the three months and nine months ended March 31, 2025 and 2024 follows:
| INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES | **** | **** | **** | **** | **** | **** | **** | **** | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | **** | **** | **** | **** | **** | **** | **** | **** | ||
| (In thousands, except share and per share amounts) | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |
| (Unaudited) | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |
| Three Months Ended | Nine Months Ended | |||||||||
| March 31, | March 31, | |||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||
| Total revenue | $ | 13,947 | $ | 13,147 | $ | 40,178 | $ | 37,571 | ||
| Cost of sales | 12,396 | 11,899 | 36,085 | 34,971 | ||||||
| Gross profit | 1,551 | 1,248 | 4,093 | 2,600 | ||||||
| Selling and administrative expenses | 812 | 893 | 2,662 | 2,751 | ||||||
| Operating income (loss) | 739 | 355 | 1,431 | (151 | ) | |||||
| Other income (expense), net | 39 | (3 | ) | 36 | 5 | |||||
| Income (loss) before income taxes | 778 | 352 | 1,467 | (146 | ) | |||||
| Income tax expense, net | 167 | 67 | 481 | 10 | ||||||
| Net income (loss) | $ | 611 | $ | 285 | $ | 986 | $ | (156 | ) | |
| Net income (loss) per common share: | ||||||||||
| Basic | $ | 0.02 | $ | 0.01 | $ | 0.03 | $ | (0.01 | ) | |
| Diluted | $ | 0.02 | $ | 0.01 | $ | 0.03 | $ | (0.01 | ) | |
| Weighted average common shares outstanding: | ||||||||||
| Basic | 30,300,720 | 30,099,610 | 30,190,869 | 30,054,883 | ||||||
| Diluted | 31,514,591 | 30,764,222 | 30,960,916 | 30,054,883 |
About Integrated BioPharma Inc. (INBP)
Integrated BioPharma, Inc. (“INBP”) is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words “expects,” “anticipates,” believes,” intends,” “estimates,” “should,” “would,” “strategy,” “plan” and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP’s products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; inflation, including inflationary pressures from any tariffs, and tightened labor markets; our ability to expand our customer base and other risks and uncertainties described in the section entitled “Risk Factors” in INBP’s most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.